3 Blue Chip Stocks Poised For A 50% Growth in The Upcoming Year (2024)🔥

5/5 - (1 vote)

Blue Chip companies are set for growth and increased cash flow next year, making them attractive for potential returns of over 50%. Consider these stable blue-chip stocks:


  1. Newmont Corporation (NEM):
    • Expecting a boost in free cash flow next year due to higher gold prices and the acquisition of Newcrest Mining.
  2. Vale (VALE):
    • Likely to rise in value as industrial commodities go up with global expansion policies.
    • Currently undervalued and has growth potential.
  3. Pfizer (PFE):
    • Growing through innovative products and strategic acquisitions.
    • Despite the recent downtrend, it presents an appealing valuation and a 6% dividend yield.

Blue-chip stocks traditionally focus on steady growth, but some, like Nvidia (NVDA) and Apple (AAPL), have seen remarkable returns recently.

Choosing the right blue-chip stocks involves identifying undervalued options and checking industry factors for potential growth.

👉 Also Read: Mondi Plc’s Special Dividend Announcement and The ZAR/Euro Exchange Dance 📢

Optimistic Outlook and Catalysts:

  • Multiple rate cuts in 2024 are expected to boost equity markets.
  • Three blue-chip stocks poised for growth in the coming quarters.

Catalysts for Optimism:

  • Industrial commodities are undervalued and may benefit from global rate cuts.
  • Vale (VALE) is undervalued with a favorable forward price-earnings ratio.
  • Pfizer (PFE) stock is undervalued, showing signs of a reversal with a 6% dividend yield.

Vale’s Potential:

  • VALE stock has a low forward price-earnings ratio of 7.3.
  • Diversification into metals supporting the global energy transition.
  • Q3 2023 EBITDA of $4.5 billion, with a potential annualized EBITDA of $20 billion.

Pfizer’s Potential:

  • PFE stock is currently undervalued, showing an appealing valuation.
  • Analysts predict a median target of $32, implying a 13% upside and nearly 20% total returns.
  • Pfizer aims for aggressive growth through clinical trials and acquisitions, with a capital expenditure of $6.5 billion in the coming year.

In conclusion, careful stock selection, considering undervaluation and industry trends, can lead to substantial returns, even in blue-chip stocks.

Source: investorplace.com

1 thought on “3 Blue Chip Stocks Poised For A 50% Growth in The Upcoming Year (2024)🔥”

Leave a Comment